Table 2.

Baseline Characteristics of the Included Trials^a

Study, year	Trial arm, dosage (mg)	N	Males	Age ± SD, y	Patient population, n
					DM	HTN	CAD	BMI
Becker et al, 200525	FBX, 80	256	243	51.8±11.7	17	106	23	32.7±6.1
	FBX, 120	251	243	52.0±12.1	17	113	28	32.3±5.7
	ALP, 300	253	243	51.6 ± 12.6	19	112	23	32.6±6.1
Schumacher et al, 200823	FBX, 80	267	251	51±12	—	124	38	33±6
	FBX, 120	269	255	51±12	—	124	37	33±7
	FBX, 240	134	126	54±13	—	70	24	33±7
	ALP, 100-300	268	249	52±12	—	123	27	33±6
	Placebo	134	123	52±12	—	61	18	32±6
Becker et al, 200918	FBX, 80	649	—	51.4±11.95	46	295	71	32.3±5.78
	FBX, 120	292	—	50.9±11.57	15	115	33	33.2±6.17
	ALP, 300	145	—	51.0±11.30	12	73	14	33.8±6.79
Becker et al, 201024	FBX, 40	757	722	52.5±11.68	89	—	421	32.9±6.37
	FBX, 80	756	710	53.0±11.79	113	—	440	32.9±6.39
	ALP, 200–300	756	709	52.9±11.73	110	—	436	32.7±6.23
Huang et al, 201429	FBX, 40	172	167	46.12±10.90	—	54	57	25.63±2.80
	FBX, 80	172	169	47.40±11.18	—	45	47	25.25±2.64
	ALP, 300	172	168	46.17±11.56	—	44	45	25.44±2.53
Nakagomi et al, 201520	FBX, 40	31	22	69.3±10	9	27	20	23.6±2.4
	ALP, 100-300	30	18	71.8±8	12	30	24	23.1±3.1
Saag et al, 201622	FBX, 30 (twice daily)	32	25	67.3±11.11	12	30	—	32.8±6.45
	FBX, 40–80 (once daily)	32	26	63.6±8.15	15	31	—	34.2±7.30
	Placebo	32	26	66.3±12.05	16	31	—	33.3±6.36
Dalbeth et al, 201726	FBX, 40–80	157	145	50.1±11.7	—	—	—	32.3±6.23
	Placebo	157	143	51.4±12.4	—	—	—	33.1±6.40
Gunawardhana et al, 201728	FBX, 80	61	50	52.2±10.5	—	43	—	31.99±5.13

^aALP = allopurinol; BMI = body mass index; CAD = coronary artery disease; DM = diabetes mellitus; ER = extended release; FBX = febuxostat; HTN = hypertension; IR = immediate release.